Maze Therapeutics to Participate in Upcoming Investor Conferences

2024-02-26

SOUTH SAN FRANCISCO, Calif--(BUSINESS WIRE)-- Maze Therapeutics a company translating genetic insights into new precision medicines, today announced that company management will participate in upcoming investor conferences in February and March 2024. Details of the events are as follows: Evercore ISI 2024 Emerging Biotech Conference Management will present during the virtual conference on Thursday, February 29, 2024 from 3:25-3:55 p.m. ET The webcast will be available live and on demand here. Cowen Healthcare Conference 2024 Management will participate in one-on-one investor meetings on Monday, March 4, 2024 Leerink Partners Global Biopharma Conference Management will participate in one-on-one investor meetings on Wednesday, March 13, 2024 About Maze Therapeutics Maze Therapeutics is a biopharmaceutical company harnessing the power of human genetics to transform the lives of patients. The Company is committed to developing breakthrough precision medicines for common diseases with large unmet medical needs. Maze has developed Maze Compass™, a proprietary, purpose-built platform to leverage insights from genetic variation and integrate the critical step of variant functionalization into each stage of therapeutic development. Utilizing Maze Compass, the Company’s strategy is to develop its therapies independently, in collaboration with major pharmaceutical companies, and through company formation. For more information, please visit mazetx.com, or follow us on LinkedIn and X (formerly Twitter).

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构